ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2676

The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27kip1 in Patients with Systemic Lupus Erythematosus

Diana Gómez-Martín1, Jorge Romo-Tena2, Javier Merayo-Chalico3, Ana Barrera-Vargas1 and Jorge Alcocer-Varela1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lupus, regulatory cells and tolerance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to suppression has been recently acknowledged as part of the defects shown by T cells from SLE patients. The E3 ligase Cbl-b has been shown to modulate T cell unresponsiveness in SLE. However its potential role in the regulation of peripheral Tregs tolerance has not been fully addressed. The aim of this study was to assess the expression of Cbl-b and its relationship to the resistance to suppression phenotype in SLE patients.

Methods: We included 25 patients with SLE (10 in remission and 15 with active untreated disease) according to the classification criteria of the American College of Rheumatology and 25 age and gender-matched healthy controls. PBMCs were isolated by density gradient and effector  (CD4+CD25–) and Tregs (CD4+CD25+CD127–) were purified by magnetic selection. The expression of Cbl-b and p27kip1 was analyzed by Western blotting. Interaction between Cbl-b and p27kip1 was addressed by immunoprecipitation (IP). Proliferative responses were assessed in allogeneic and autologous cocultures by CFSE. Differences were assessed by t Student test. p<0.05 was considered as statistically significant. In all cases, an informed consent was obtained, and the ethics committee approved this study. 

Results: We found diminished Cbl-b expression in Tregs from SLE patients in comparison to healthy controls (1.3±1.0 vs 2.8±1.8, p=0.002), which was associated with resistance to suppression in proliferation assays (r=0.553, p=0.041). Moreover, this phenomenon was related to deficient expression of the cell cycle regulator p27kip1 in Tregs from SLE patients when compared to healthy controls. We also found by IP assays, that p27kip1 interacts with Cbl-b in Tregs. We found no significant differences regarding to disease activity.

Conclusion: Our data suggest that the ligase Cbl-b is able to regulate the interplay between effector and Tregs, particularly, the resistance to suppression via ubiquitination of p27kip1 in SLE patients. To our knowledge, this is the first study to demonstrate that p27kip1 is able to interact with Cbl-b, which might constitute another mechanism by which this ubiquitin ligase is able to modulate the T cell receptor activation threshold.


Disclosure:

D. Gómez-Martín,
None;

J. Romo-Tena,
None;

J. Merayo-Chalico,
None;

A. Barrera-Vargas,
None;

J. Alcocer-Varela,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-e3-ligase-casitas-b-lineage-lymphoma-b-cbl-b-modulates-peripheral-regulatory-t-cell-function-via-p27kip1-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology